Analyst Thinks Johnson & Johnson Could Hit a $280 Target
A major analyst raises the price target on Johnson & Johnson to $280, arguing growing oncology sales and a planned sp...
Daily volatility influences return paths and allocation choices. This primer covers interpretation and practical tweaks to targets and expectations.
25,212 articlesA major analyst raises the price target on Johnson & Johnson to $280, arguing growing oncology sales and a planned sp...
The Federal Reserve held rates steady this week, but uncertainty remains. Three principal concerns are rattling inves...
Investing in rare earths sits at the intersection of policy, manufacturing demand, and new mining projects. This guid...
A 58-year-old nurse with 230K saved is advised to buy a condo and ramp retirement funding, with a potential 350K inhe...
European Union and United States trade talks accelerate, threatening tariff changes that could ripple through inflati...
Abcellera's Q1 2026 earnings transcript provides key clues about the path to 2026. This guide breaks down revenue dri...
Markets are weighing policy moves that could lift earnings for select U.S. tech and EV names. Here are the players mo...
Could Nvidia's stock really reach $300 by late 2026? This article breaks down the odds, the driving forces behind the...
SpaceX's S-1 filing exposes Bitcoin exposure and a broader digital-asset playbook, signaling a new price benchmark fo...
Investors are weighing two very different quantum paths. This guide compares D-Wave Quantum and IonQ, highlighting te...
Mexican President Claudia Sheinbaum escalated claims that the United States is meddling in domestic affairs after a h...
Morgan’s Analyst Focus List for June highlights five top passive-income dividend ideas, signaling a cautious but inco...